Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA4 | P22748 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.32 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9070629 | 0.94 | CA2 (0.42) | CA2CA4CA1CA6PTPN1 | |
| SCHEMBL17772634 | 0.88 | CA2 (0.39) | CA2CA4CA1CA6PTPN1 | |
| SCHEMBL11268433 | 0.85 | CA2 (0.40) | CA2CA4CA1CA6PTPN1 | |
| SCHEMBL21883813 | 0.85 | CA2 (0.40) | CA2CA4CA1CA6PTPN1 | |
| SCHEMBL14946904 | 0.82 | CA2 (0.39) | CA2CA4CA1CA6PTPN1 | |
| SCHEMBL14098922 | 0.82 | CA2 (0.39) | CA2CA4CA1CA6PTPN1 | |
| SCHEMBL1275689 | 0.82 | CA2 (0.44) | CA2CA4CA1CA6PTPN1 | |
| SCHEMBL2952712 | 0.80 | ACHE (0.40) | CA2CA4CA1CA6ALDH1A1 | |
| SCHEMBL8250446 | 0.80 | CA2 (0.42) | CA2CA4CA1CA6PTPN1 | |
| SCHEMBL9814080 | 0.80 | CA2 (0.42) | CA2CA4CA1CA6PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11724996-B2 | Synthesis of intermediates for the preparation of alpha-tocopherol | DSM IP ASSETS B.V. (NL) | 2023-08-15 | — | — | US | disclosed |
| US-11724996-B2 | Synthesis of intermediates for the preparation of alpha-tocopherol | DSM IP ASSETS B.V. (NL) | 2023-08-15 | — | — | US | disclosed |
| US-11724996-B2 | Synthesis of intermediates for the preparation of alpha-tocopherol | DSM IP ASSETS B.V. (NL) | 2023-08-15 | — | — | US | disclosed |
| EP-3652162-B1 | NOVEL SYNTHESIS OF INTERMEDIATES FOR THE PREPARATION OF ALPHA-TOCOPHEROL | DSM IP ASSETS BV (NL) | 2023-02-22 | — | — | EP | disclosed |
| EP-3652162-B1 | NOVEL SYNTHESIS OF INTERMEDIATES FOR THE PREPARATION OF ALPHA-TOCOPHEROL | DSM IP ASSETS BV (NL) | 2023-02-22 | — | — | EP | disclosed |
| US-20210300886-A1 | SYNTHESIS OF INTERMEDIATES FOR THE PREPARATION OF ALPHA-TOCOPHEROL | DSM IP ASSETS BV (NL) | 2021-09-30 | — | — | US | disclosed |
| EP-3652162-A1 | NOVEL SYNTHESIS OF INTERMEDIATES FOR THE PREPARATION OF ALPHA-TOCOPHEROL | DSM IP Assets B.V. (NL) | 2020-05-20 | — | — | EP | disclosed |
| US-20200131145-A1 | NOVEL SYNTHESIS OF INTERMEDIATES FOR THE PREPARATION OF ALPHA-TOCOPHEROL | DSM IP ASSETS B.V. (NL) | 2020-04-30 | — | — | US | disclosed |
| CN-111065634-A | Novel synthesis of intermediate for preparing α -tocopherol | 帝斯曼知识产权资产管理有限公司 | 2020-04-24 | — | — | CN | disclosed |
| EP-2970158-B1 | ALKYL-HETEROARYL SUBSTITUTED QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | BIOELECTRON TECH CORP (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-0171251-B1 | QUINONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1990-06-27 | — | — | EP | disclosed |
| US-4857516-A | Coumaran derivatives and their pharmaceutical use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-08-15 | — | — | US | disclosed |
| US-4851413-A | TREATMENT OF HEART, BRAIN, LUNG OR KIDNEY DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-07-25 | — | — | US | disclosed |
| EP-0273647-A1 | Coumaran derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1988-07-06 | — | — | EP | disclosed |
| EP-0234729-A2 | Quinone derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-09-02 | — | — | EP | disclosed |
| EP-0171251-A2 | Quinone derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-02-12 | — | — | EP | disclosed |
| US-4270003-A | Hydroquinone derivatives and preparation thereof | KURARAY CO., LTD. (JP) | 1981-05-26 | — | — | US | disclosed |
| US-4234490-A | Intermediates in the synthesis of vitamin E | HOFFMANN-LA ROCHE INC. (US) | 1980-11-18 | — | — | US | disclosed |
| US-4201879-A | Hydroquinones | HOFFMANN-LA ROCHE INC. (US) | 1980-05-06 | — | — | US | disclosed |
| US-4153614-A | Synthesis of (S)-(+)-6-hydroxy-2,5,7,8-tetramethylchroman-2-methanol and intermediates therein | HOFFMANN-LA ROCHE INC. (US) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300886-A1 | SYNTHESIS OF INTERMEDIATES FOR THE PREPARATION OF ALPHA-TOCOPHEROL | TTPA, DHPS, SQLE | CA2 4840/4885CA4 4519/4885CA1 4615/4885 |
| US-20200131145-A1 | NOVEL SYNTHESIS OF INTERMEDIATES FOR THE PREPARATION OF ALPHA-TOCOPHEROL | TTPA, VKORC1, SQLE | CA2 4868/4885CA4 4622/4885CA1 4688/4885 |
| US-11724996-B2 | Synthesis of intermediates for the preparation of alpha-tocopherol | TTPA, DHPS, SQLE | CA2 4840/4885CA4 4519/4885CA1 4615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.